Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis
The expert panel discusses recent data regarding the mechanisms of resistance to non-covalent BTK inhibitors in CLL.
EP: 1.Current Front-Line Treatment Options for CLL in 2023
EP: 2.Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA
EP: 3.Strategies for Managing Treatment-Naïve CLL with High-Risk Features
EP: 4.Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL
EP: 5.Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL
EP: 6.Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy
EP: 7.Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE
EP: 8.Expert Perspectives on Navigating Treatment Selection with BTKis in CLL
EP: 9.Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy
EP: 10.Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice
EP: 11.Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials
Now Viewing
EP: 12.Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis
EP: 13.Expert Insights into Investigation Therapies for CLL
EP: 14.Future Perspectives on the Treatment Landscape for CLL
Related Videos
Related Content
